Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May 10;39(5):594-596.
doi: 10.1016/j.ccell.2021.03.008. Epub 2021 Apr 15.

Seeing the forest for the trees-single-cell atlases link CD8+ T cells and macrophages to disease progression and treatment response in kidney cancer

Mei Yee Koh  1 , Nicolas Sayegh  2 , Neeraj Agarwal  3
Affiliations
Free article
Comment

Seeing the forest for the trees-single-cell atlases link CD8+ T cells and macrophages to disease progression and treatment response in kidney cancer

Mei Yee Koh et al. Cancer Cell. .
Free article

Abstract

Intra- and interpatient heterogeneity of clear cell renal cell carcinoma (ccRCC) confounds the search for therapies associated with durable tumor responses and predictive biomarkers. Here, Braun et. al., Krishna et.al, and Bi et.al. use single-cell mRNA sequencing to characterize progressive immune dysfunction associated with ccRCC progression and resistance to immunotherapies.

Keywords: CD8(+) T cells; biomarkers; immune checkpoint blockade; kidney cancer; macrophage; single-cell RNA sequencing.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests M.Y.K. is founder and has equity in Kuda Therapeutics Inc. N.S. reports no conflicts of interest. N.A. reports consultancy and personal fees from the following: Astellas, Astra Zeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics.

Comment on

  • Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.
    Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, Grimaldi G, Braun DA, Cuoco MS, Mayorga A, DelloStritto L, Bouchard G, Steinharter J, Tewari AK, Vokes NI, Shannon E, Sun M, Park J, Chang SL, McGregor BA, Haq R, Denize T, Signoretti S, Guerriero JL, Vigneau S, Rozenblatt-Rosen O, Rotem A, Regev A, Choueiri TK, Van Allen EM. Bi K, et al. Cancer Cell. 2021 May 10;39(5):649-661.e5. doi: 10.1016/j.ccell.2021.02.015. Epub 2021 Mar 11. Cancer Cell. 2021. PMID: 33711272 Free PMC article.
  • Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.
    Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, Cui A, Keskin DB, Steinharter J, Bouchard G, Sun M, Pimenta EM, Xu W, Mahoney KM, McGregor BA, Hirsch MS, Chang SL, Livak KJ, McDermott DF, Shukla SA, Olsen LR, Signoretti S, Sharpe AH, Irizarry RA, Choueiri TK, Wu CJ. Braun DA, et al. Cancer Cell. 2021 May 10;39(5):632-648.e8. doi: 10.1016/j.ccell.2021.02.013. Epub 2021 Mar 11. Cancer Cell. 2021. PMID: 33711273 Free PMC article.
  • Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy.
    Krishna C, DiNatale RG, Kuo F, Srivastava RM, Vuong L, Chowell D, Gupta S, Vanderbilt C, Purohit TA, Liu M, Kansler E, Nixon BG, Chen YB, Makarov V, Blum KA, Attalla K, Weng S, Salmans ML, Golkaram M, Liu L, Zhang S, Vijayaraghavan R, Pawlowski T, Reuter V, Carlo MI, Voss MH, Coleman J, Russo P, Motzer RJ, Li MO, Leslie CS, Chan TA, Hakimi AA. Krishna C, et al. Cancer Cell. 2021 May 10;39(5):662-677.e6. doi: 10.1016/j.ccell.2021.03.007. Epub 2021 Apr 15. Cancer Cell. 2021. PMID: 33861994 Free PMC article.

LinkOut - more resources